NCT05191485 Shared Decision Making in Patients With Lung Cancer
| NCT ID | NCT05191485 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sichuan Cancer Hospital and Research Institute |
| Condition | Surgery |
| Study Type | OBSERVATIONAL |
| Enrollment | 190 participants |
| Start Date | 2023-02-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 190 participants in total. It began in 2023-02-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to develop a Decision Aid for Lung Cancer Molecular Testing (DA\_LCMT) and to facilitate shared-decision making in patients who were diagnosed with lung adenocarcinoma by intraoperative frozen pathology about whether to conduct the molecular testing.
Eligibility Criteria
Inclusion criteria: Patients of decision-making need assessment: 1\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have or have not made a decision on lung cancer molecular testing (whether to perform molecular testing or not). Other stakeholders of decision-making need assessment: 1\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process. Patients of Cognitive debriefing/Alpha tests: 1\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have made a decision on whether to perform lung cancer molecular testing or not. other stakeholders of Cognitive debriefing/Alpha tests: 1\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process. Patients of field testing /Beta tests: 1\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have not decided whether to perform lung cancer molecular testing or not. Clinician of field testing /Beta tests: 1\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; and 4) voluntarily participated in this study. Exclusion criteria: Inability to understand the research content.
Frequently Asked Questions
Who can join the NCT05191485 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05191485 currently recruiting?
Yes, NCT05191485 is actively recruiting participants. Visit ClinicalTrials.gov or contact Sichuan Cancer Hospital and Research Institute to inquire about joining.
Where is the NCT05191485 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT05191485 clinical trial?
NCT05191485 is sponsored by Sichuan Cancer Hospital and Research Institute. The trial plans to enroll 190 participants.